In this paper, I compare activities in biotech firms in the two countries based on firm-level data in 2004 (443 Japanese firms, 12 of which are listed publicly, and 1,446 US firms, 431 of which are public). First, I found that Japanese firms are much smaller than US firms, even after controlling...